Polyrizon announces board authorized exploration of investment opportunities

Polyrizon (PLRZ) recently announced that its Board of Directors has authorized the exploration of strategic investment opportunities in select revenue-generating assets. Polyrizon is focusing its initial efforts on operating companies in high-potential sectors, including defense, aviation, and artificial intelligence. The Company remains fully committed to its core medical device activities, continuing to advance product development, preclinical and clinical studies, and regulatory progress – including products such as PL-14, PL-16, and the Trap & Target platform for intranasal drug delivery. In parallel, leveraging the Company’s strong cash position and debt-free balance sheet, the Company’s Board of Directors has approved pursing selective investments that are expected to generate near-term revenues, enhance financial stability and create additional value for shareholders.